Nykode Therapeutics AS announced a private placement of up to 29,549,400 new common shares at a price of NOK 11.167739 per share for the gross proceeds of up to NOK 329,999,986.8066 on October 24, 2023. The transaction will include participation from existing shareholders as well as other Norwegian and international investors. The completion of the Private Placement by delivery of offer shares to applicants is subject to the Board resolving to complete the Private Placement including the issuance of up to 29,549,400 Offer Shares pertaining to the Private Placement pursuant to the authorization granted by the annual general meeting of the company held on 11 May 2023, the placing agreement between the company and the Joint Global Coordinators and the Joint Bookrunner entered into in connection with the Private Placement not being terminated by the Managers in accordance with the terms thereof and the SLA remaining in full force and effect.

Subject to completion of the Private Placement, the company, the members of the Board and the executive management have agreed to a lock-up period of 180 days from the completion of the Private Placement, subject to customary exceptions.